Brain iron accumulation in aging and neurodegenerative disorders

References

• Beard JL, Connor JR. Iron status and neural functioning. Annu. Rev. Nutr. 23, 41–58 (2003).
   PubMed Web of Science ®Google Scholar
• Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J. Neurochem. 3(1), 41–51 (1958).
   PubMed Web of Science ®Google Scholar
• Dröge W, Schipper HM. Oxidative stress and aberrant signaling in aging and cognitive decline. Aging Cell 6(3), 361–370 (2007).
   PubMed Web of Science ®Google Scholar
• Gerlach M, Ben-Shachar D, Riederer P, Youdim MB. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63(3), 793–807 (1994).
   PubMed Web of Science ®Google Scholar
• Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5(11), 863–873 (2004).
   PubMed Web of Science ®Google Scholar
• Beard J. Iron deficiency alters brain development and functioning. J. Nutr. 133(5 Suppl. 1), 1468S–1472S (2003).
   PubMed Web of Science ®Google Scholar
• Beard JL, Connor JR, Jones BC. Iron in the brain. Nutr. Rev. 51(6), 157–170 (1993).
   PubMed Web of Science ®Google Scholar
• Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta 1275(3), 161–203 (1996).
   PubMed Web of Science ®Google Scholar
• Mims MP, Prchal JT. Divalent metal transporter 1. Hematology 10(4), 339–345 (2005).
   PubMed Web of Science ®Google Scholar
• Anderson GJ, Vulpe CD. Mammalian iron transport. Cell. Mol. Life Sci. 66(20), 3241–3261 (2009).
   PubMed Web of Science ®Google Scholar
• Andrews NC. Iron homeostasis: insights from genetics and animal models. Nat. Rev. Genet. 1(3), 208–217 (2000).
   PubMed Web of Science ®Google Scholar
• Crichton RR, Dexter DT, Ward RJ. Brain iron metabolism and its perturbation in neurological diseases. J. Neural Transm. 118(3), 301–314 (2011).
   PubMed Web of Science ®Google Scholar
• Harris ZL, Durley AP, Man TK, Gitlin JD. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc. Natl Acad. Sci. USA 96(19), 10812–10817 (1999).
   PubMed Web of Science ®Google Scholar
• Texel SJ, Camandola S, Ladenheim B et al. Ceruloplasmin deficiency results in an anxiety phenotype involving deficits in hippocampal iron, serotonin, and BDNF. J. Neurochem. 120(1), 125–134 (2012).
   PubMed Web of Science ®Google Scholar
• Kidane TZ, Sauble E, Linder MC. Release of iron from ferritin requires lysosomal activity. Am. J. Physiol., Cell Physiol. 291(3), C445–C455 (2006).
   PubMed Web of Science ®Google Scholar
• Terman A, Kurz T. Lysosomal iron, iron chelation and cell death. Antioxid. Redox Signal. doi:10.1089/ars.2012.4885 (2012) (Epub ahead of print).
   PubMedGoogle Scholar
• Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306(5704), 2090–2093 (2004).
   PubMed Web of Science ®Google Scholar
• Crichton RR, Wilmet S, Legssyer R, Ward RJ. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J. Inorg. Biochem. 91(1), 9–18 (2002).
   PubMed Web of Science ®Google Scholar
• Moos T, Skjoerringe T, Gosk S, Morgan EH. Brain capillary endothelial cells mediate iron transport into the brain by segregating iron from transferrin without the involvement of divalent metal transporter 1. J. Neurochem. 98(6), 1946–1958 (2006).
   PubMed Web of Science ®Google Scholar
• Morgan EH, Moos T. Mechanism and developmental changes in iron transport across the blood-brain barrier. Dev. Neurosci. 24(2–3), 106–113 (2002).
   PubMed Web of Science ®Google Scholar
• Moos T, Rosengren Nielsen T, Skjørringe T, Morgan EH. Iron trafficking inside the brain. J. Neurochem. 103(5), 1730–1740 (2007).
   PubMed Web of Science ®Google Scholar
• Youdim MB, Ben-Shachar D, Yehuda S. Putative biological mechanisms of the effect of iron deficiency on brain biochemistry and behavior. Am. J. Clin. Nutr. 50(Suppl. 3), 607–615; discussion 615 (1989).
   PubMed Web of Science ®Google Scholar
• Connor JR, Ponnuru P, Wang XS, Patton SM, Allen RP, Earley CJ. Profile of altered brain iron acquisition in restless legs syndrome. Brain 134(Pt 4), 959–968 (2011).
   PubMed Web of Science ®Google Scholar
• Rouault TA, Zhang DL, Jeong SY. Brain iron homeostasis, the choroid plexus, and localization of iron transport proteins. Metab. Brain Dis. 24(4), 673–684 (2009).
   PubMed Web of Science ®Google Scholar
• Xu J, Marzetti E, Seo AY, Kim JS, Prolla TA, Leeuwenburgh C. The emerging role of iron dyshomeostasis in the mitochondrial decay of aging. Mech. Ageing Dev. 131(7–8), 487–493 (2010).
   PubMed Web of Science ®Google Scholar
• Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? Nat. Med. 10(Suppl.), S18–S25 (2004).
   PubMedGoogle Scholar
• Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 59(5), 1609–1623 (1992).
   PubMed Web of Science ®Google Scholar
• Jomova K, Valko M. Advances in metal-induced oxidative stress and human disease. Toxicology 283(2–3), 65–87 (2011).
   PubMed Web of Science ®Google Scholar
• Liang LP, Jarrett SG, Patel M. Chelation of mitochondrial iron prevents seizure-induced mitochondrial dysfunction and neuronal injury. J. Neurosci. 28(45), 11550–11556 (2008).
   PubMed Web of Science ®Google Scholar
• Millerot-Serrurot E, Bertrand N, Mossiat C et al. Temporal changes in free iron levels after brain ischemia Relevance to the timing of iron chelation therapy in stroke. Neurochem. Int. 52(8), 1442–1448 (2008).
   PubMed Web of Science ®Google Scholar
• Bains JS, Shaw CA. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res. Brain Res. Rev. 25(3), 335–358 (1997).
   PubMed Web of Science ®Google Scholar
• Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl Acad. Sci. USA 90(17), 7915–7922 (1993).
   PubMed Web of Science ®Google Scholar
• Atwood CS, Obrenovich ME, Liu T et al. Amyloid-β: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-β. Brain Res. Brain Res. Rev. 43(1), 1–16 (2003).
   PubMed Web of Science ®Google Scholar
• Kontush A. Amyloid-β: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer’s disease. Free Radic. Biol. Med. 31(9), 1120–1131 (2001).
   PubMed Web of Science ®Google Scholar
• Smith MA, Casadesus G, Joseph JA, Perry G. Amyloid-β and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic. Biol. Med. 33(9), 1194–1199 (2002).
   PubMed Web of Science ®Google Scholar
• Koeppen AH. The history of iron in the brain. J. Neurol. Sci. 134(Suppl.), 1–9 (1995).
   PubMed Web of Science ®Google Scholar
• Bartzokis G, Beckson M, Hance DB, Marx P, Foster JA, Marder SR. MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn. Reson. Imaging 15(1), 29–35 (1997).
   PubMed Web of Science ®Google Scholar
• Connor JR, Menzies SL, St Martin SM, Mufson EJ. Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J. Neurosci. Res. 27(4), 595–611 (1990).
   PubMed Web of Science ®Google Scholar
• Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer’s diseased brains. J. Neurochem. 65(2), 717–724 (1995).
   PubMed Web of Science ®Google Scholar
• Zecca L, Gallorini M, Schünemann V et al. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 76(6), 1766–1773 (2001).
   PubMed Web of Science ®Google Scholar
• Hirose W, Ikematsu K, Tsuda R. Age-associated increases in heme oxygenase-1 and ferritin immunoreactivity in the autopsied brain. Leg. Med. 5(Suppl. 1), 360–366 (2003).
   PubMedGoogle Scholar
• Maines MD. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J. 2(10), 2557–2568 (1988).
   PubMed Web of Science ®Google Scholar
• Schipper HM, Song W, Zukor H, Hascalovici JR, Zeligman D. Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement. J. Neurochem. 110(2), 469–485 (2009).
   PubMed Web of Science ®Google Scholar
• Bartzokis G, Marder SR. Magnetic resonance imaging evaluation of brain iron levels. Biol. Psychiatry 38(2), 133–135 (1995).
   PubMed Web of Science ®Google Scholar
• Bartzokis G, Mintz J, Sultzer D et al. In vivo MR evaluation of age-related increases in brain iron. AJNR Am. J. Neuroradiol. 15(6), 1129–1138 (1994).
   PubMed Web of Science ®Google Scholar
• Thomas LO, Boyko OB, Anthony DC, Burger PC. MR detection of brain iron. AJNR Am. J. Neuroradiol. 14(5), 1043–1048 (1993).
   PubMed Web of Science ®Google Scholar
• Aoki S, Okada Y, Nishimura K et al. Normal deposition of brain iron in childhood and adolescence: MR imaging at 1.5 T. Radiology 172(2), 381–385 (1989).
   PubMed Web of Science ®Google Scholar
• Aquino D, Bizzi A, Grisoli M et al. Age-related iron deposition in the basal ganglia: quantitative analysis in healthy subjects. Radiology 252(1), 165–172 (2009).
   PubMed Web of Science ®Google Scholar
• Cherubini A, Péran P, Caltagirone C, Sabatini U, Spalletta G. Aging of subcortical nuclei: microstructural, mineralization and atrophy modifications measured in vivo using MRI. Neuroimage 48(1), 29–36 (2009).
   PubMed Web of Science ®Google Scholar
• Martin WR, Ye FQ, Allen PS. Increasing striatal iron content associated with normal aging. Mov. Disord. 13(2), 281–286 (1998).
   PubMed Web of Science ®Google Scholar
• Péran P, Cherubini A, Luccichenti G et al. Volume and iron content in basal ganglia and thalamus. Hum. Brain Mapp. 30(8), 2667–2675 (2009).
   PubMed Web of Science ®Google Scholar
• Bilgic B, Pfefferbaum A, Rohlfing T, Sullivan EV, Adalsteinsson E. MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Neuroimage 59(3), 2625–2635 (2012).
   PubMed Web of Science ®Google Scholar
• Pfefferbaum A, Adalsteinsson E, Rohlfing T, Sullivan EV. MRI estimates of brain iron concentration in normal aging: comparison of field-dependent (FDRI) and phase (SWI) methods. Neuroimage 47(2), 493–500 (2009).
   PubMed Web of Science ®Google Scholar
• Xu X, Wang Q, Zhang M. Age, gender, and hemispheric differences in iron deposition in the human brain: an in vivo MRI study. Neuroimage 40(1), 35–42 (2008).
   PubMed Web of Science ®Google Scholar
• Antharam V, Collingwood JF, Bullivant JP et al. High field magnetic resonance microscopy of the human hippocampus in Alzheimer’s disease: quantitative imaging and correlation with iron. Neuroimage 59(2), 1249–1260 (2012).
   PubMed Web of Science ®Google Scholar
• Bagnato F, Hametner S, Yao B et al. Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain 134(Pt 12), 3602–3615 (2011).
   PubMed Web of Science ®Google Scholar
• Lotfipour AK, Wharton S, Schwarz ST et al. High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson’s disease. J. Magn. Reson. Imaging 35(1), 48–55 (2012).
   PubMed Web of Science ®Google Scholar
• Penke L, Valdés Hernandéz MC, Maniega SM et al. Brain iron deposits are associated with general cognitive ability and cognitive aging. Neurobiol. Aging 33(3), 510–517.e2 (2012).
   PubMed Web of Science ®Google Scholar
• Sullivan EV, Adalsteinsson E, Rohlfing T, Pfefferbaum A. Relevance of iron deposition in deep gray matter brain structures to cognitive and motor performance in healthy elderly men and women: exploratory findings. Brain Imaging Behav. 3(2), 167–175 (2009).
   PubMed Web of Science ®Google Scholar
• Harman D. Free radical theory of aging. Mutat. Res. 275(3–6), 257–266 (1992).
   PubMed Web of Science ®Google Scholar
• Lee CK, Klopp RG, Weindruch R, Prolla TA. Gene expression profile of aging and its retardation by caloric restriction. Science 285(5432), 1390–1393 (1999).
   PubMed Web of Science ®Google Scholar
• Kennedy BK, Steffen KK, Kaeberlein M. Ruminations on dietary restriction and aging. Cell. Mol. Life Sci. 64(11), 1323–1328 (2007).
   PubMed Web of Science ®Google Scholar
• Mair W, Dillin A. Aging and survival: the genetics of life span extension by dietary restriction. Annu. Rev. Biochem. 77, 727–754 (2008).
   PubMed Web of Science ®Google Scholar
• Masoro EJ. Caloric restriction and aging: an update. Exp. Gerontol. 35(3), 299–305 (2000).
   PubMed Web of Science ®Google Scholar
• Sharma PK, Mittal N, Deswal S, Roy N. Calorie restriction up-regulates iron and copper transport genes in Saccharomyces cerevisiae. Mol. Biosyst. 7(2), 394–402 (2011).
   PubMedGoogle Scholar
• Bonilla E, Medina-Leendertz S, Díaz S. Extension of life span and stress resistance of Drosophila melanogaster by long-term supplementation with melatonin. Exp. Gerontol. 37(5), 629–638 (2002).
   PubMed Web of Science ®Google Scholar
• Melov S, Ravenscroft J, Malik S et al. Extension of life-span with superoxide dismutase/catalase mimetics. Science 289(5484), 1567–1569 (2000).
   PubMed Web of Science ®Google Scholar
• Massie HR, Aiello VR, Williams TR. Inhibition of iron absorption prolongs the life span of Drosophila. Mech. Ageing Dev. 67(3), 227–237 (1993).
   PubMed Web of Science ®Google Scholar
• Gakh O, Park S, Liu G et al. Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity. Hum. Mol. Genet. 15(3), 467–479 (2006).
   PubMed Web of Science ®Google Scholar
• Lapointe J, Hekimi S. When a theory of aging ages badly. Cell. Mol. Life Sci. 67(1), 1–8 (2010).
   PubMed Web of Science ®Google Scholar
• Whitfield JB, Treloar S, Zhu G, Powell LW, Martin NG. Relative importance of female-specific and non-female-specific effects on variation in iron stores between women. Br. J. Haematol. 120(5), 860–866 (2003).
   PubMed Web of Science ®Google Scholar
• Milman N. Serum ferritin in Danes: studies of iron status from infancy to old age, during blood donation and pregnancy. Int. J. Hematol. 63(2), 103–135 (1996).
   PubMed Web of Science ®Google Scholar
• Zacharski LR, Ornstein DL, Woloshin S, Schwartz LM. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am. Heart J. 140(1), 98–104 (2000).
   PubMed Web of Science ®Google Scholar
• Bartzokis G, Tishler TA, Lu PH et al. Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol. Aging 28(3), 414–423 (2007).
   PubMed Web of Science ®Google Scholar
• Haaxma CA, Bloem BR, Borm GF et al. Gender differences in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr. 78(8), 819–824 (2007).
   PubMed Web of Science ®Google Scholar
• Bartzokis G, Tishler TA, Shin IS, Lu PH, Cummings JL. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann. NY Acad. Sci. 1012, 224–236 (2004).
   PubMed Web of Science ®Google Scholar
• Bartzokis G, Lu PH, Tishler TA et al. Prevalent iron metabolism gene variants associated with increased brain ferritin iron in healthy older men. J. Alzheimers Dis. 20(1), 333–341 (2010).
   PubMed Web of Science ®Google Scholar
• Tishler TA, Raven EP, Lu PH, Altshuler LL, Bartzokis G. Premenopausal hysterectomy is associated with increased brain ferritin iron. Neurobiol. Aging 33(9), 1950–1958 (2012).
   PubMed Web of Science ®Google Scholar
• Sazawal S, Black RE, Ramsan M et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. Lancet 367(9505), 133–143 (2006).
   PubMed Web of Science ®Google Scholar
• WHO. Conclusions and recommendations of the WHO consultation on prevention and control of iron deficiency in infants and young children in malaria-endemic areas. Food Nutr. Bull. 28, 621–627 (2007).
   Google Scholar
• MursuJ, RobienK, HarnackLJ, ParkK, JacobsDR Jr. Dietary supplements and mortality rate in older women: the Iowa Women’s Health Study. Arch. Intern. Med. 171(18), 1625–1633 (2011).
   PubMed Web of Science ®Google Scholar
• Polla AS, Polla LL, Polla BS. Iron as the malignant spirit in successful ageing. Ageing Res. Rev. 2(1), 25–37 (2003).
   PubMed Web of Science ®Google Scholar
• Bissett DL, McBride JF. Synergistic topical photoprotection by a combination of the iron chelator 2-furildioxime and sunscreen. J. Am. Acad. Dermatol. 35(4), 546–549 (1996).
   PubMed Web of Science ®Google Scholar
• Bissett DL, Chatterjee R, Hannon DP. Chronic ultraviolet radiation-induced increase in skin iron and the photoprotective effect of topically applied iron chelators. Photochem. Photobiol. 54(2), 215–223 (1991).
   PubMed Web of Science ®Google Scholar
• Bissett DL, Oelrich DM, Hannon DP. Evaluation of a topical iron chelator in animals and in human beings: short-term photoprotection by 2-furildioxime. J. Am. Acad. Dermatol. 31(4), 572–578 (1994).
   PubMed Web of Science ®Google Scholar
• Tuomainen TP, Kontula K, Nyyssönen K, Lakka TA, Heliö T, Salonen JT. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation: a prospective cohort study in men in eastern Finland. Circulation 100(12), 1274–1279 (1999).
   PubMed Web of Science ®Google Scholar
• Roest M, van der Schouw YT, de Valk B et al. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation 100(12), 1268–1273 (1999).
   PubMed Web of Science ®Google Scholar
• Allen KJ, Gurrin LC, Constantine CC et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N. Engl. J. Med. 358(3), 221–230 (2008).
   PubMed Web of Science ®Google Scholar
• Nandar W, Connor JR. HFE gene variants affect iron in the brain. J. Nutr. 141(4), S729–S739 (2011).
   PubMed Web of Science ®Google Scholar
• Ristic S, Lovrecic L, Brajenovic-Milic B et al. Mutations in the hemochromatosis gene (HFE) and multiple sclerosis. Neurosci. Lett. 383(3), 301–304 (2005).
   PubMed Web of Science ®Google Scholar
• Rubio JP, Bahlo M, Tubridy N et al. Extended haplotype analysis in the HLA complex reveals an increased frequency of the HFE-C282Y mutation in individuals with multiple sclerosis. Hum. Genet. 114(6), 573–580 (2004).
   PubMed Web of Science ®Google Scholar
• Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60(8), 1119–1122 (2003).
   PubMed Web of Science ®Google Scholar
• Plassman BL, Langa KM, Fisher GG et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 29(1–2), 125–132 (2007).
   PubMed Web of Science ®Google Scholar
• Kester MI, Scheltens P. Dementia: the bare essentials. Pract. Neurol. 9(4), 241–251 (2009).
   PubMedGoogle Scholar
• Jack CR Jr, Petersen RC, Xu YC et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer’s disease. Neurology 49(3), 786–794 (1997).
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580), 353–356 (2002).
   PubMed Web of Science ®Google Scholar
• Kang J, Lemaire HG, Unterbeck A et al. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325(6106), 733–736 (1987).
   PubMed Web of Science ®Google Scholar
• Nunan J, Small DH. Regulation of APP cleavage by α-, β- and γ-secretases. FEBS Lett. 483(1), 6–10 (2000).
   PubMed Web of Science ®Google Scholar
• Small DH, McLean CA. Alzheimer’s disease and the amyloid β protein: What is the role of amyloid? J. Neurochem. 73(2), 443–449 (1999).
   PubMed Web of Science ®Google Scholar
• Yan Y, Wang C. Aβ42 is more rigid than Aβ40 at the C terminus: implications for Aβ aggregation and toxicity. J. Mol. Biol. 364(5), 853–862 (2006).
   PubMed Web of Science ®Google Scholar
• Maynard CJ, Bush AI, Masters CL, Cappai R, Li QX. Metals and amyloid-β in Alzheimer’s disease. Int. J. Exp. Pathol. 86(3), 147–159 (2005).
   PubMed Web of Science ®Google Scholar
• Klein WL, Krafft GA, Finch CE. Targeting small Aβ oligomers: the solution to an Alzheimer’s disease conundrum? Trends Neurosci. 24(4), 219–224 (2001).
   PubMed Web of Science ®Google Scholar
• Bush AI, Tanzi RE. Therapeutics for Alzheimer’s disease based on the metal hypothesis. Neurotherapeutics 5(3), 421–432 (2008).
   PubMed Web of Science ®Google Scholar
• Duce JA, Tsatsanis A, Cater MA et al. Iron-export ferroxidase activity of ß-amyloid precursor protein is inhibited by zinc in Alzheimer’s disease. Cell 142(6), 857–867 (2010).
   PubMed Web of Science ®Google Scholar
• Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer’s disease. J. Neurosci. Res. 31(2), 327–335 (1992).
   PubMed Web of Science ®Google Scholar
• LeVine SM. Iron deposits in multiple sclerosis and Alzheimer’s disease brains. Brain Res. 760(1–2), 298–303 (1997).
   PubMed Web of Science ®Google Scholar
• Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer’s disease senile plaques. J. Neurol. Sci. 158(1), 47–52 (1998).
   PubMed Web of Science ®Google Scholar
• Schrag M, Mueller C, Oyoyo U, Smith MA, Kirsch WM. Iron, zinc and copper in the Alzheimer’s disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Prog. Neurobiol. 94(3), 296–306 (2011).
   PubMed Web of Science ®Google Scholar
• Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A, Miklossy J. Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with β-amyloid deposits in Alzheimer’s disease. J. Struct. Biol. 155(1), 30–37 (2006).
   PubMed Web of Science ®Google Scholar
• Rottkamp CA, Raina AK, Zhu X et al. Redox-active iron mediates amyloid-β toxicity. Free Radic. Biol. Med. 30(4), 447–450 (2001).
   PubMed Web of Science ®Google Scholar
• Honda K, Casadesus G, Petersen RB, Perry G, Smith MA. Oxidative stress and redox-active iron in Alzheimer’s disease. Ann. NY Acad. Sci. 1012, 179–182 (2004).
   PubMed Web of Science ®Google Scholar
• Bishop GM, Robinson SR, Liu Q, Perry G, Atwood CS, Smith MA. Iron: a pathological mediator of Alzheimer disease? Dev. Neurosci. 24(2–3), 184–187 (2002).
   PubMed Web of Science ®Google Scholar
• Atwood CS, Robinson SR, Smith MA. Amyloid-β: redox-metal chelator and antioxidant. J. Alzheimers Dis. 4(3), 203–214 (2002).
   PubMed Web of Science ®Google Scholar
• Yan SD, Yan SF, Chen X et al. Non-enzymatically glycated tau in Alzheimer’s disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide. Nat. Med. 1(7), 693–699 (1995).
   PubMed Web of Science ®Google Scholar
• Castellani RJ, Lee HG, Perry G, Smith MA. Antioxidant protection and neurodegenerative disease: the role of amyloid-β and tau. Am. J. Alzheimers. Dis. Other Demen. 21(2), 126–130 (2006).
   PubMedGoogle Scholar
• Tamagno E, Guglielmotto M, Aragno M et al. Oxidative stress activates a positive feedback between the γ- and β-secretase cleavages of the β-amyloid precursor protein. J. Neurochem. 104(3), 683–695 (2008).
   PubMed Web of Science ®Google Scholar
• Bartzokis G, Sultzer D, Mintz J et al. In vivo evaluation of brain iron in Alzheimer’s disease and normal subjects using MRI. Biol. Psychiatry 35(7), 480–487 (1994).
   PubMed Web of Science ®Google Scholar
• Bartzokis G, Sultzer D, Cummings J et al. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch. Gen. Psychiatry 57(1), 47–53 (2000).
   PubMed Web of Science ®Google Scholar
• Bartzokis G, Tishler TA. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer’s and Huntingon’s disease. Cell. Mol. Biol. (Noisy-le-grand) 46(4), 821–833 (2000).
   PubMed Web of Science ®Google Scholar
• House MJ, St Pierre TG, Foster JK, Martins RN, Clarnette R. Quantitative MR imaging R2 relaxometry in elderly participants reporting memory loss. AJNR Am. J. Neuroradiol. 27(2), 430–439 (2006).
   PubMed Web of Science ®Google Scholar
• Smith MA, Zhu X, Tabaton M et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J. Alzheimers Dis. 19(1), 363–372 (2010).
   PubMed Web of Science ®Google Scholar
• Leskovjan AC, Kretlow A, Lanzirotti A, Barrea R, Vogt S, Miller LM. Increased brain iron coincides with early plaque formation in a mouse model of Alzheimer’s disease. Neuroimage 55(1), 32–38 (2011).
   PubMed Web of Science ®Google Scholar
• Ling HW, Ding B, Wang T, Zhang H, Chen KM. Could iron accumulation be an etiology of the white matter change in Alzheimer’s disease: using phase imaging to detect white matter iron deposition based on diffusion tensor imaging. Dement. Geriatr. Cogn. Disord. 31(4), 300–308 (2011).
   PubMed Web of Science ®Google Scholar
• van Rensburg SJ, Carstens ME, Potocnik FC, Aucamp AK, Taljaard JJ. Increased frequency of the transferrin C2 subtype in Alzheimer’s disease. Neuroreport 4(11), 1269–1271 (1993).
   PubMed Web of Science ®Google Scholar
• Namekata K, Imagawa M, Terashi A, Ohta S, Oyama F, Ihara Y. Association of transferrin C2 allele with late-onset Alzheimer’s disease. Hum. Genet. 101(2), 126–129 (1997).
   PubMed Web of Science ®Google Scholar
• Moalem S, Percy ME, Andrews DF et al. Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am. J. Med. Genet. 93(1), 58–66 (2000).
   PubMed Web of Science ®Google Scholar
• Sampietro M, Caputo L, Casatta A et al. The hemochromatosis gene affects the age of onset of sporadic Alzheimer’s disease. Neurobiol. Aging 22(4), 563–568 (2001).
   PubMed Web of Science ®Google Scholar
• Alizadeh BZ, Njajou OT, Millán MR, Hofman A, Breteler MM, van Duijn CM. HFE variants, APOE and Alzheimer’s disease: findings from the population-based Rotterdam study. Neurobiol. Aging 30(2), 330–332 (2009).
   PubMed Web of Science ®Google Scholar
• Lin M, Zhao L, Fan J et al. Association between HFE polymorphisms and susceptibility to Alzheimer’s disease: a meta-analysis of 22 studies including 4,365 cases and 8,652 controls. Mol. Biol. Rep. 39(3), 3089–3095 (2012).
   PubMed Web of Science ®Google Scholar
• Sian-Hülsmann J, Mandel S, Youdim MB, Riederer P. The relevance of iron in the pathogenesis of Parkinson’s disease. J. Neurochem. 118(6), 939–957 (2011).
   PubMed Web of Science ®Google Scholar
• Dexter DT, Carayon A, Javoy-Agid F et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114 (Pt 4), 1953–1975 (1991).
   PubMed Web of Science ®Google Scholar
• Morawski M, Meinecke C, Reinert T et al. Determination of trace elements in the human substantia nigra. Nucl. Instrum. Methods B 231(1–4), 224–228 (2005).
   Web of Science ®Google Scholar
• Jin L, Wang J, Jin H et al. Nigral iron deposition occurs across motor phenotypes of Parkinson’s disease. Eur. J. Neurol. 19(7), 969–976 (2012).
   PubMed Web of Science ®Google Scholar
• Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA. Increased iron-related MRI contrast in the substantia nigra in Parkinson’s disease. Neurology 45(6), 1138–1143 (1995).
   PubMed Web of Science ®Google Scholar
• Atasoy HT, Nuyan O, Tunc T, Yorubulut M, Unal AE, Inan LE. T2-weighted MRI in Parkinson’s disease; substantia nigra pars compacta hypointensity correlates with the clinical scores. Neurol. India 52(3), 332–337 (2004).
   PubMed Web of Science ®Google Scholar
• Wallis LI, Paley MN, Graham JM et al. MRI assessment of basal ganglia iron deposition in Parkinson’s disease. J. Magn. Reson. Imaging 28(5), 1061–1067 (2008).
   PubMed Web of Science ®Google Scholar
• Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 70(16 Pt 2), 1411–1417 (2008).
   PubMed Web of Science ®Google Scholar
• Du G, Lewis MM, Styner M et al. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson’s disease. Mov. Disord. 26(9), 1627–1632 (2011).
   PubMed Web of Science ®Google Scholar
• Zucca FA, Bellei C, Giannelli S et al. Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability. J. Neural Transm. 113(6), 757–767 (2006).
   PubMed Web of Science ®Google Scholar
• Aime S, Bergamasco B, Casu M et al. Isolation and 13C-NMR characterization of an insoluble proteinaceous fraction from substantia nigra of patients with Parkinson’s disease. Mov. Disord. 15(5), 977–981 (2000).
   PubMed Web of Science ®Google Scholar
• Shamoto-Nagai M, Maruyama W, Yi H et al. Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome. J. Neural Transm. 113(5), 633–644 (2006).
   PubMed Web of Science ®Google Scholar
• Friedman A, Galazka-Friedman J, Koziorowski D. Iron as a cause of Parkinson disease – a myth or a well established hypothesis? Parkinsonism Relat. Disord. 15(Suppl. 3), S212–S214 (2009).
   PubMedGoogle Scholar
• SpillantiniMG, CrowtherRA, JakesR, HasegawaM, GoedertM. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc. Natl Acad. Sci. USA 95(11), 6469–6473 (1998).
   PubMed Web of Science ®Google Scholar
• ChandraS, GallardoG, Fernández-ChacónR, SchlüterOM, SüdhofTC. α-Synuclein cooperates with CSPα in preventing neurodegeneration. Cell 123(3), 383–396 (2005).
   PubMed Web of Science ®Google Scholar
• SpillantiniMG, SchmidtML, LeeVM, TrojanowskiJQ, JakesR, GoedertM. α-synuclein in Lewy bodies. Nature 388(6645), 839–840 (1997).
   PubMed Web of Science ®Google Scholar
• Lee HG, Zhu X, Takeda A, Perry G, Smith MA. Emerging evidence for the neuroprotective role of α-synuclein. Exp. Neurol. 200(1), 1–7 (2006).
   PubMed Web of Science ®Google Scholar
• Ostrerova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, Wolozin B. The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20(16), 6048–6054 (2000).
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Takeda A, Hsu LJ, Takenouchi T, Masliah E. Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy body disease. J. Biol. Chem. 274(41), 28849–28852 (1999).
   PubMed Web of Science ®Google Scholar
• Riederer P, Sofic E, Rausch WD et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52(2), 515–520 (1989).
   PubMed Web of Science ®Google Scholar
• Dexter DT, Sian J, Jenner P, Marsden CD. Implications of alterations in trace element levels in brain in Parkinson’s disease and other neurological disorders affecting the basal ganglia. Adv. Neurol. 60, 273–281 (1993).
   PubMedGoogle Scholar
• Khalil M, Teunissen C, Langkammer C. Iron and neurodegeneration in multiple sclerosis. Mult. Scler. Int. 2011, 606807 (2011).
   PubMedGoogle Scholar
• Pirko I, Lucchinetti CF, Sriram S, Bakshi R. Gray matter involvement in multiple sclerosis. Neurology 68(9), 634–642 (2007).
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Heininen-Brown M, Schirda CV et al. Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case–control study. Neuroimage 59(1), 331–339 (2012).
   PubMed Web of Science ®Google Scholar
• Bakshi R, Dmochowski J, Shaikh ZA, Jacobs L. Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients. J. Neurol. Sci. 185(1), 19–26 (2001).
   PubMed Web of Science ®Google Scholar
• Neema M, Arora A, Healy BC et al. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J. Neuroimaging 19(1), 3–8 (2009).
   PubMed Web of Science ®Google Scholar
• Tjoa CW, Benedict RH, Weinstock-Guttman B, Fabiano AJ, Bakshi R. MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis. J. Neurol. Sci. 234(1–2), 17–24 (2005).
   PubMed Web of Science ®Google Scholar
• Brass SD, Benedict RH, Weinstock-Guttman B, Munschauer F, Bakshi R. Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. Mult. Scler. 12(4), 437–444 (2006).
   PubMed Web of Science ®Google Scholar
• Hagemeier J, Weinstock-Guttman B, Bergsland N et al. Iron deposition on SWI-filtered phase in the subcortical deep gray matter of patients with clinically isolated syndrome may precede structure-specific atrophy. AJNR Am. J. Neuroradiol. 33(8), 1596–1601 (2012).
   PubMed Web of Science ®Google Scholar
• Ceccarelli A, Rocca MA, Neema M et al. Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis. Mult. Scler. 16(1), 39–44 (2010).
   PubMed Web of Science ®Google Scholar
• Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden–Spatz syndrome. Nat. Genet. 28(4), 345–349 (2001).
   PubMed Web of Science ®Google Scholar
• Miyajima H, Takahashi Y, Kono S. Aceruloplasminemia, an inherited disorder of iron metabolism. Biometals 16(1), 205–213 (2003).
   PubMed Web of Science ®Google Scholar
• Chinnery PF, Crompton DE, Birchall D et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 130(Pt 1), 110–119 (2007).
   PubMed Web of Science ®Google Scholar
• Koutnikova H, Campuzano V, Foury F, Dollé P, Cazzalini O, Koenig M. Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nat. Genet. 16(4), 345–351 (1997).
   PubMed Web of Science ®Google Scholar
• Schneider SA, Hardy J, Bhatia KP. Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations. Mov. Disord. 27(1), 42–53 (2012).
   PubMed Web of Science ®Google Scholar
• Ke Y, Qian ZM. Brain iron metabolism: neurobiology and neurochemistry. Prog. Neurobiol. 83(3), 149–173 (2007).
   PubMed Web of Science ®Google Scholar
• Gregory A, Hayflick SJ. Genetics of neurodegeneration with brain iron accumulation. Curr. Neurol. Neurosci. Rep. 11(3), 254–261 (2011).
   PubMed Web of Science ®Google Scholar
• Miyajima H, Adachi J, Tatsuno Y et al. Increased very long-chain fatty acids in erythrocyte membranes of patients with aceruloplasminemia. Neurology 50(1), 130–136 (1998).
   PubMed Web of Science ®Google Scholar
• Kenche VB, Barnham KJ. Alzheimer’s disease & metals: therapeutic opportunities. Br. J. Pharmacol. 163(2), 211–219 (2011).
   PubMed Web of Science ®Google Scholar
• Prass K, Ruscher K, Karsch M et al. Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro. J. Cereb. Blood Flow Metab. 22(5), 520–525 (2002).
   PubMed Web of Science ®Google Scholar
• Crapper McLachlan DR, Dalton AJ, Kruck TP et al. Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet 337(8753), 1304–1308 (1991).
   PubMed Web of Science ®Google Scholar
• Cherny RA, Atwood CS, Xilinas ME et al. Treatment with a copper–zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron 30(3), 665–676 (2001).
   PubMed Web of Science ®Google Scholar
• Ritchie CW, Bush AI, Mackinnon A et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot Phase 2 clinical trial. Arch. Neurol. 60(12), 1685–1691 (2003).
   PubMed Web of Science ®Google Scholar
• Adlard PA, Cherny RA, Finkelstein DI et al. Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ. Neuron 59(1), 43–55 (2008).
   PubMed Web of Science ®Google Scholar
• Faux NG, Ritchie CW, Gunn A et al. PBT2 rapidly improves cognition in Alzheimer’s Disease: additional Phase II analyses. J. Alzheimers Dis. 20(2), 509–516 (2010).
   PubMed Web of Science ®Google Scholar
• Lannfelt L, Blennow K, Zetterberg H et al.; PBT2-201-EURO study group. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer’s disease: a Phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 7(9), 779–786 (2008).
   PubMed Web of Science ®Google Scholar
• Crouch PJ, Savva MS, Hung LW et al. The Alzheimer’s therapeutic PBT2 promotes amyloid-ß degradation and GSK3 phosphorylation via a metal chaperone activity. J. Neurochem. 119(1), 220–230 (2011).
   PubMed Web of Science ®Google Scholar
• Perez CA, Tong Y, Guo M. Iron chelators as potential therapeutic agents for Parkinson’s disease. Curr. Bioact. Compd. 4(3), 150–158 (2008).
   PubMedGoogle Scholar
• Ben-Shachar D, Eshel G, Finberg JP, Youdim MB. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56(4), 1441–1444 (1991).
   PubMed Web of Science ®Google Scholar
• Jiang H, Luan Z, Wang J, Xie J. Neuroprotective effects of iron chelator Desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload. Neurochem. Int. 49(6), 605–609 (2006).
   PubMed Web of Science ®Google Scholar
• Pedchenko TV, LeVine SM. Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice. J. Neuroimmunol. 84(2), 188–197 (1998).
   PubMed Web of Science ®Google Scholar
• Mitchell KM, Dotson AL, Cool KM, Chakrabarty A, Benedict SH, LeVine SM. Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis. Mult. Scler. 13(9), 1118–1126 (2007).
   PubMed Web of Science ®Google Scholar
• Lynch SG, Fonseca T, LeVine SM. A multiple course trial of desferrioxamine in chronic progressive multiple sclerosis. Cell. Mol. Biol. (Noisy-le-grand) 46(4), 865–869 (2000).
   PubMed Web of Science ®Google Scholar
• Kaur D, Yantiri F, Rajagopalan S et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson’s disease. Neuron 37(6), 899–909 (2003).
   PubMed Web of Science ®Google Scholar
• Wilson RB. Therapeutic developments in Friedreich ataxia. J. Child Neurol. 27(9), 1212–1216 (2012).
   PubMed Web of Science ®Google Scholar
• Dexter DT, Statton SA, Whitmore C et al. Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson’s disease after peripheral administration. J. Neural Transm. 118(2), 223–231 (2011).
   PubMed Web of Science ®Google Scholar
• Leed MG, Wolkow N, Pham DM, Daniel CL, Dunaief JL, Franz KJ. Prochelators triggered by hydrogen peroxide provide hexadentate iron coordination to impede oxidative stress. J. Inorg. Biochem. 105(9), 1161–1172 (2011).
   PubMed Web of Science ®Google Scholar
• Wei Y, Guo M. Hydrogen peroxide triggered prochelator activation, subsequent metal chelation, and attenuation of the fenton reaction. Angew. Chem. Int. Ed. Engl. 46(25), 4722–4725 (2007).
   PubMed Web of Science ®Google Scholar
• Mercer LD, Kelly BL, Horne MK, Beart PM. Dietary polyphenols protect dopamine neurons from oxidative insults and apoptosis: investigations in primary rat mesencephalic cultures. Biochem. Pharmacol. 69(2), 339–345 (2005).
   PubMed Web of Science ®Google Scholar
• Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J. Nutr. 130(8S Suppl.), S2073S–S2085 (2000).
   Google Scholar
• Mandel SA, Amit T, Weinreb O, Youdim MB. Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases. J. Alzheimers Dis. 25(2), 187–208 (2011).
   PubMed Web of Science ®Google Scholar
• Rahman I, Biswas SK, Kirkham PA. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem. Pharmacol. 72(11), 1439–1452 (2006).
   PubMed Web of Science ®Google Scholar
• Sun AY, Simonyi A, Sun GY. The ‘French Paradox’ and beyond: neuroprotective effects of polyphenols. Free Radic. Biol. Med. 32(4), 314–318 (2002).
   PubMed Web of Science ®Google Scholar
• Scapagnini G, Caruso C, Calabrese V. Therapeutic potential of dietary polyphenols against brain ageing and neurodegenerative disorders. Adv. Exp. Med. Biol. 698, 27–35 (2010).
   PubMed Web of Science ®Google Scholar
• Levites Y, Weinreb O, Maor G, Youdim MB, Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem. 78(5), 1073–1082 (2001).
   PubMed Web of Science ®Google Scholar
• Joseph JA, Shukitt-Hale B, Denisova NA et al. Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation. J. Neurosci. 19(18), 8114–8121 (1999).
   PubMed Web of Science ®Google Scholar
• Reznichenko L, Kalfon L, Amit T, Youdim MB, Mandel SA. Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism. Neurodegener. Dis. 7(4), 219–231 (2010).
   PubMed Web of Science ®Google Scholar